SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 8-K
Document Type: EX-1.1
Date Filed: 2025-08-27
Accession Number: 0001213900-25-081175
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025081175/ea025480001ex1-1_synergy.htm

Chunk 14 of 27
Word Count: 1235
Character Count: 7669

Document Content:

party, (ii) a conflict or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party and the indemnifying party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the indemnified party), or (iii) the indemnifying party has not in fact employed counsel reasonably satisfactory to the indemnified party to assume the defense of such action within a reasonable time after receiving notice of the commencement of the action, the indemnified party shall have the right to employ a single counsel to represent it in any claim in respect of which indemnity may be sought under subsection (a) or (b) of this Section 7, in which event the reasonable fees and expenses of such separate counsel shall be borne by the indemnifying party or parties and reimbursed to the indemnified party as incurred.

The indemnifying party under
this Section 7 shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such
consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any
loss, claim, damage, liability or expense by reason of such settlement or judgment. No indemnifying party shall, without the prior written
consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action,
suit or proceeding in respect of which any indemnified party is a party or could be named and indemnity was or would be sought hereunder
by such indemnified party, unless such settlement, compromise or consent (a) includes an unconditional release of such indemnified party
from all liability for claims that are the subject matter of such action, suit or proceeding and (b) does not include a statement as to
or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.

(d) If the indemnification provided
for in this Section 7 is unavailable or insufficient to hold harmless an indemnified party under subsection (a) or (b) above, then each
indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of the losses, claims, damages
or liabilities referred to in subsection (a) or (b) above, (i) in such proportion as is appropriate to reflect the relative benefits received
by the Company on the one hand and the Underwriters on the other from the Offering and sale of the Shares or (ii) if the allocation provided
by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to in clause (i) above but also the relative fault of the Company on the one hand and the Underwriters on the other in connection
with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other shall be deemed to be
in the same proportion as the total net proceeds from the Offering (before deducting expenses) received by the Company compared to the
total underwriting discount received by the Underwriters, in each case as set forth in the table on the cover page of the Final Prospectus,
and the value of the Representative Warrants received by the Underwriters. The relative fault shall be determined by reference to, among
other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material
fact relates to information supplied by the Company or the Underwriters and the parties’ relevant intent, knowledge, access to information
and opportunity to correct or prevent such untrue statement or omission. The Company and the Underwriters agree that it would not be just
and equitable if contributions pursuant to this subsection (d) were to be determined by pro rata allocation or by any other method of
allocation that does not take account of the equitable considerations referred to in the first sentence of this subsection (d). The amount
paid by an indemnified party as a result of the losses, claims, damages or liabilities referred to in the first sentence of this subsection
(d) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating
or defending against any action or claim that is the subject of this subsection (d). Notwithstanding the provisions of this subsection
(d), no Underwriter shall be required to contribute any amount in excess of the amount of the underwriting discount applicable to the
Shares to be purchased by the Underwriters hereunder actually received by the Underwriters and the value of the Representative Warrants
received by the Representative. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities
Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters’
respective obligations to contribute as provided in this Section 7 are several in proportion to their respective underwriting commitments
and not joint.

(e) The obligations of the Company
under this Section 7 shall be in addition to any liability that the Company may otherwise have and the benefits of such obligations shall
extend, upon the same terms and conditions, to each person, if any, who controls the Underwriters within the meaning of Section 15 of
the Securities Act or Section 20 of the Exchange Act; and the obligations of the Underwriters under this Section 7 shall be in addition
to any liability that the Underwriters may otherwise have and the benefits of such obligations shall extend, upon the same terms and conditions,
to the Company, its officers, directors and each person who controls the Company within the meaning of Section 15 of the Securities Act
or Section 20 of the Exchange Act.

(f) For purposes of this Agreement,
the Representative confirms, and the Company acknowledges, that there is no information concerning the Underwriters furnished in writing
to the Company by the Underwriters specifically for preparation of or inclusion in the Registration Statement, the Time of Sale Disclosure
Package, any Prospectus, the Final Prospectus or any Issuer Free Writing Prospectus, other than the statement set forth in the last paragraph
on the cover page of the Prospectus, the marketing and legal names of the Underwriters, and the statements set forth in the “Underwriting”
section of the Registration Statement, the Time of Sale Disclosure Package, and the Final Prospectus only insofar as such statements relate
to the amount of selling concession and re-allowance, if any, or to over-allotment, stabilization and related activities that may be undertaken
by the Underwriters.

8. Representations and
Agreements to Survive Delivery. All representations, warranties, and agreements of the Company contained herein or in certificates
delivered pursuant hereto, including, but not limited to, the agreements of the several Underwriters and the Company contained in Section
5(a)(viii) and Section 7 hereof, shall remain operative and in full force and effect regardless of any investigation made by or on behalf
of the Underwriters or any controlling person thereof, or the Company, any of its officers, directors, or controlling persons, and shall
survive delivery of, and payment for, the Shares and the Representative Warrants.

9. Termination of this
Agreement.